Breast Cancer Liquid Biopsy Market Report Scope & Overview:

The Breast Cancer Liquid Biopsy Market was valued at USD 1.33 Billion in 2025 and is expected to reach USD 3.42 Billion by 2035, growing at a CAGR of 8.61% from 2026 to 2035.

The global breast cancer liquid biopsy market is growing at a strong pace as the shift toward precision oncology, growing clinical adoption of non-invasive tumor monitoring, and regulatory approval expansion for liquid biopsy-based companion diagnostics create demand for circulating biomarker testing. The market is driven by the growing recognition that more than 70% of oncologists now incorporate liquid biopsy to guide targeted therapy decisions in breast cancer, FDA-approved liquid biopsy platforms, the increasing application of liquid biopsy in treatment monitoring and minimal residual disease detection, and the expanding research into early detection applications where cfDNA sensitivity exceeding 85% for early-stage breast cancer detection suggests potential as a population screening supplement to mammography.

In 2024, Guardant Health received FDA supplemental approval for Guardant360 CDx as a companion diagnostic for additional HER2-low and ESR1 mutation-targeted therapies in metastatic breast cancer, expanding the commercially reimbursable clinical indication base that sustains above-commodity liquid biopsy test pricing beyond the research and monitoring use cases that preceded companion diagnostic regulatory approval in driving structured health system procurement.

Market Size and Forecast

• Market Size in 2026E: USD 1.44 Billion

• Market Size by 2035: USD 3.42 Billion

• CAGR: 8.61% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Breast Cancer Liquid Biopsy Market Trends

• Multi-cancer detection panels are expanding liquid biopsy applications beyond breast cancer toward broader population-scale screening programs.

• ctDNA-based minimal residual disease monitoring is increasing recurring test volumes through ongoing treatment response and recurrence assessment.

• AI-driven data interpretation improves mutation detection sensitivity and specificity, enabling earlier and more accurate breast cancer diagnosis.

• Extracellular vesicle biomarkers provide complementary proteomic and transcriptomic insights beyond conventional cfDNA-based liquid biopsy testing.

• Decentralized sample collection technologies support home-based testing, improving patient convenience and longitudinal monitoring adoption rates.

U.S. Breast Cancer Liquid Biopsy Market Outlook

The U.S. Breast Cancer Liquid Biopsy Market was valued at approximately USD 0.39 Billion in 2025 and is expected to reach approximately USD 0.84 Billion by 2035, growing at a CAGR of approximately 7.4%.

The U.S. is the world's most commercially significant breast cancer liquid biopsy market, driven by greater FDA approvals, expanding insurance coverage, and increased investments in precision oncology making tests more accessible for early-stage and metastatic breast cancer management. Guardant Health, Foundation Medicine, Illumina, Exact Sciences, Tempus AI, and NeoGenomics collectively define the domestic breast cancer liquid biopsy commercial landscape. Medicare coverage expansion for companion diagnostic liquid biopsy testing in metastatic breast cancer, the extraordinary concentration of U.S. oncology drug development whose companion diagnostic requirements create clinical indication expansion for liquid biopsy assays, and the U.S. healthcare system's above-global-average per-patient oncology spending sustain the domestic market's commercial leadership position.

In 2023, Foundation Medicine expanded its FoundationOne Liquid CDx clinical indications to include ESR1 mutation detection for guidance of elacestrant treatment in HR-positive HER2-negative metastatic breast cancer, creating a new FDA-approved companion diagnostic indication that adds Medicare-reimbursable liquid biopsy test volume from the large population of metastatic hormone receptor-positive breast cancer patients who progress on first-line endocrine therapy.

Breast Cancer Liquid Biopsy Market Segment Analysis

• By Product, the assay kits segmented dominated the market with approximately 53% share in 2025 and is expected to be the fastest growing segment.

• By Biomarkers, the circulating cell-free DNA (cfDNA) segment dominated the market with approximately 50.7% share in 2025, while the circulating tumor cells (CTCs) segment is the fastest growing.

• By Application, the treatment selection segment dominated the market with approximately 48.4% share in 2025, while the early detection/screening segment is the fastest growing.

By Biomarkers, cfDNA dominates, CTCs grow fastest

Circulating cell-free DNA retained the dominant biomarker position with approximately 50.7% of the breast cancer liquid biopsy market in 2025. cfDNA's commercial primacy reflects the combination of established analytical methodology, FDA-approved companion diagnostic platform commercialization, and clinical guideline integration for metastatic breast cancer genomic profiling that creates reimbursable clinical demand. The high sensitivity of next-generation sequencing-based ctDNA analysis for detecting tumor-specific mutations at allele fractions below 0.1%, whose performance enables detection of PIK3CA, ESR1, and HER2 mutations in the heavily pre-treated metastatic breast cancer setting where tissue re-biopsy faces practical limitations, creates clinical utility that sustains specification preference among oncologists.

Circulating tumor cells are the fastest growing biomarker because the clinical community's recognition of CTCs’ unique information value beyond cfDNA’s DNA-sequence characterization creates above-average research and clinical investment in CTC isolation and analysis technology. CTCs provide intact cancer cells from peripheral blood whose whole-cell biological characterization including protein expression, receptor status, and viability enables treatment sensitivity assessment that cfDNA fragmentary analysis cannot provide with equivalent biological fidelity. Each clinical programme that validates CTC-based treatment response prediction creates commercial momentum for CTC test adoption among oncologists whose patient management benefits from real-time tumor biology characterization beyond genomic mutation profiling.

By Application, treatment selection dominates, early detection grows fastest

Treatment selection retained the dominant application position with approximately 48.4% of the breast cancer liquid biopsy market in 2025. The FDA's companion diagnostic approval pathway creates a commercially validated clinical indication for treatment selection liquid biopsy whose reimbursement certainty, prescribing guideline inclusion, and clinical utility evidence base sustain consistent health system procurement. Each FDA companion diagnostic approval that creates a new treatment selection indication for liquid biopsy testing creates a new structured commercial opportunity whose patient population size and testing frequency creates defined commercial market expansion.

Early detection and screening is the fastest growing application because the potential of liquid biopsy to serve as a non-invasive cancer screening tool in the population at risk for breast cancer creates an application category whose theoretical commercial scale substantially exceeds current clinical diagnosis and monitoring applications. GRAIL's Galleri multi-cancer early detection test, whose clinical evidence for pre-symptomatic breast cancer detection at above-80% sensitivity in some stage categories creates regulatory pathway motivation, and the growing investment in cfDNA-based early cancer detection research collectively create the most commercially transformative near-term application expansion opportunity.

Regional Analysis

North America Breast Cancer Liquid Biopsy Market Insights

North America dominated the global breast cancer liquid biopsy market in 2025, driven by FDA approval expansion for companion diagnostic liquid biopsy indications, growing Medicare and private insurer coverage of clinically validated liquid biopsy tests, and the extraordinary concentration of precision oncology investment and clinical research infrastructure. The United States accounts for approximately 87.4% of North American revenues through Guardant Health, Foundation Medicine, Tempus AI, Exact Sciences, and NeoGenomics’ commercial operations.

Canada contributes approximately 12.6% of North American revenues through the Canadian Cancer Society's research investment, provincial health system coverage for validated liquid biopsy indications, and the growing precision oncology programme infrastructure at major cancer centres including Princess Margaret, the BC Cancer Agency, and the McGill University Health Centre.

Europe Breast Cancer Liquid Biopsy Market Insights

Europe is a technically sophisticated breast cancer liquid biopsy market where the European Medicines Agency’s companion diagnostic approval framework, national health technology assessment bodies’ reimbursement decisions, and the ESMO breast cancer guidelines’ clinical indication recommendations create structured institutional demand. Germany accounts for approximately 22.3% of European revenues through its oncology research infrastructure, the statutory health insurance system's reimbursement policy, and the pharmaceutical industry’s clinical trial investment creating clinical evidence that sustains guideline inclusion.

The United Kingdom, France, and the Netherlands are significant secondary markets where NHS Genomic Medicine Service’s molecular testing programme, Institut Curie’s precision oncology leadership, and the Netherlands Cancer Institute’s clinical research sustain above-average European liquid biopsy adoption. Roche’s and Illumina’s European operations sustain regional commercial supply.

Asia Pacific Breast Cancer Liquid Biopsy Market Insights

Asia Pacific is the fastest growing regional breast cancer liquid biopsy market, driven by China's growing oncology healthcare investment, Japan's advanced precision medicine programme, South Korea's biotech innovation, and the region's extraordinary breast cancer burden whose incidence creates structured clinical demand. China accounts for approximately 44.8% of Asia Pacific revenues through Burning Rock Biotech's and Berry Oncology's domestic liquid biopsy platforms, the NMPA's companion diagnostic approval expansion, and the growing private oncology hospital sector's molecular testing adoption.

India represents the most commercially dynamic emerging market within Asia Pacific where the growing private oncology sector's precision medicine investment, the expanding access to NGS-based molecular testing through reference laboratory networks, and the government's national cancer programme investment create above-average breast cancer liquid biopsy procurement growth.

MEA & Latin America Breast Cancer Liquid Biopsy Market Insights

Israel leads MEA revenues at approximately 31.2% through its globally significant oncology research sector, Maccabi Healthcare Services’ precision oncology programme, and the domestic biotech sector's genomic diagnostics investment. Saudi Arabia's Vision 2030 oncology healthcare infrastructure and the UAE’s Cleveland Clinic Abu Dhabi programme add Gulf demand.

Brazil leads Latin American revenues at approximately 44.2% through the INCA national cancer institute, the Fleury Medicina group's molecular oncology services, and the growing private oncology sector's precision medicine adoption. Mexico's oncology infrastructure and Argentina's genomic medicine capability collectively sustain regional growth through 2035.

Market Dynamics

Growth Drivers: Precision oncology adoption creating treatment selection liquid biopsy demand and FDA companion diagnostic approval expansion creating reimbursable clinical indications

The growing shift toward precision oncology in breast cancer management is the market's most commercially transformative structural growth driver. More than 70% of oncologists incorporating liquid biopsy as an important treatment guidance tool creates structured consistent clinical demand that sustains above-commodity test pricing. Each targeted therapy approval that specifies companion diagnostic testing for patient selection creates a new FDA-reimbursable liquid biopsy clinical indication whose patient population size and standard-of-care inclusion create defined commercial procurement. The FDA's approval of Guardant360 CDx and FoundationOne Liquid CDx for multiple metastatic breast cancer companion diagnostic indications creates commercial infrastructure whose reimbursement stability sustains laboratory investment in liquid biopsy testing capacity.

FDA approval expansion for liquid biopsy companion diagnostics creates the most commercially certain near-term growth driver whose regulatory milestone events create defined commercial market expansions. Each PIK3CA, ESR1, and HER2 mutation companion diagnostic approval that adds a new reimbursable indication for an established liquid biopsy platform creates incremental testing volume whose per-patient commercial value sustains laboratory platform investment.

Restraints: Regulatory standardization absence and reimbursement coverage limitations

The absence of globally harmonized standards for liquid biopsy testing creates inconsistency in clinical utilization that limits the pace of guideline inclusion and health system procurement expansion. Each liquid biopsy test that produces inconsistent results across different platforms and laboratories from equivalent patient samples creates prescriber confidence concerns that moderate broader clinical adoption beyond companion diagnostic applications. The FDA and EMA's strict validation requirements for new clinical indications create regulatory timelines that delay commercial expansion from research evidence to reimbursable clinical practice.

Reimbursement coverage limitations from Medicare and private insurers whose coverage policies extend to specific companion diagnostic indications while leaving non-companion-diagnostic monitoring, early detection, and research applications unreimbursed create patient access barriers that limit market expansion beyond the companion diagnostic application.

Opportunities: Multi-cancer early detection platforms and MRD monitoring for treatment response guidance

Multi-cancer early detection represents the most commercially transformative long-term breast cancer liquid biopsy opportunity whose population-scale health system deployment would create commercial scale substantially exceeding current companion diagnostic clinical indication markets. GRAIL's Galleri test clinical validation programme and the growing investment in cfDNA-based cancer screening algorithm development collectively create regulatory pathway momentum that sustains commercial development investment. Each MCED programme that achieves clinical utility validation for breast cancer early detection creates a defined regulatory approval opportunity whose health system procurement scale at population screening frequency creates the most commercially significant potential expansion of the liquid biopsy market.

Minimal residual disease monitoring for treatment response guidance represents the most near-term clinically validated commercial expansion opportunity whose serial ctDNA assessment capability creates per-patient test volume that single-episode companion diagnostic testing cannot approach. Each breast cancer patient whose MRD monitoring programme creates quarterly or monthly liquid biopsy test orders creates cumulative annual test volume whose per-patient commercial value sustains programme adoption investment from oncology practices and health systems whose clinical outcome improvement from MRD-guided treatment adaptation creates measurable value.

Recent Developments:

• 2025: Guardant Health secured FDA approval for Guardant360 CDx in ESR1-mutated advanced breast cancer, expanding liquid biopsy use in precision oncology treatment selection.

• 2025: Natera launched the ultra-sensitive Signatera Genome MRD assay, enabling earlier ctDNA detection and enhanced breast cancer recurrence monitoring capabilities.

• 2025: Exact Sciences introduced Cancerguard, a multi-cancer blood-based screening test, strengthening adoption of liquid biopsy technologies for early cancer detection.

• 2025: NHS England expanded liquid biopsy testing for breast cancer patients, enabling faster genomic profiling, personalized treatment decisions, and reduced reliance on invasive tissue biopsies.

Breast Cancer Liquid Biopsy Market key players are:

• Guardant Health Inc.

• Foundation Medicine Inc. (Roche)

• Illumina Inc.

• Exact Sciences Corporation

• Tempus AI Inc.

• NeoGenomics Laboratories Inc.

• Natera Inc.

• GRAIL LLC (Illumina)

• Veracyte Inc.

• Burning Rock Biotech Ltd.

• Berry Oncology Corp.

• Inivata Ltd. (NeoGenomics)

• Biocept Inc.

• CellMax Life Inc.

• Menarini Silicon Biosystems SpA

• Angle plc

• QIAGEN N.V.

• F. Hoffmann-La Roche Ltd.

• Personalis, Inc.

• Lucence Diagnostics Pte. Ltd.

Breast Cancer Liquid Biopsy Market Report Scope: